Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ascletis PharmaASCLF 38 Days Sales Outstanding is 60.61 as of Dec. 2025, which is 62% below its 10-year median of 160.40. GuruFocus rates ASCLF with a GF Score™ of 38/100 and a GF Value™ of $0.02 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 837 Biotechnology companies, Ascletis Pharma ranks better than 67.98% on this metric.
Ascletis Pharma (OTCPK:ASCLF) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Ascletis Pharma Days Sales Outstanding Related Terms
Ascletis Pharma Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Ascletis Pharma's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASCLF vs VRTX, REGN, RVMD: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Ascletis Pharma's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascletis Pharma Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ascletis Pharma's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Ascletis Pharma's Days Sales Outstanding falls into.
Ascletis Pharma Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascletis Pharma (ASCLF) has a Days Sales Outstanding of 60.61 as of Dec. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Ascletis Pharma and its competitors. This is 62% below median its historical median of 160.40. Over the past decade, Ascletis Pharma's Days Sales Outstanding has ranged from 33.24 to 812.99. According to the industry distribution chart, Ascletis Pharma ranks #268 out of 837 companies in the Biotechnology industry, placing it in the top 32%.
Is Ascletis Pharma's Days Sales Outstanding too high?
Ascletis Pharma's current Days Sales Outstanding of 60.61 is 62% below median its 10-year median of 160.40. Over the past 10 years, this metric has ranged from a low of 33.24 to a high of 812.99. The Biotechnology industry median Days Sales Outstanding is 68.42. Ascletis Pharma's value of 60.61 is 11.4% below this industry median. Based on the distribution chart, Ascletis Pharma ranks #268 out of 837 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ascletis Pharma has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ascletis Pharma's Days Sales Outstanding compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ascletis Pharma ranks #268 out of 837 companies for Days Sales Outstanding. This puts Ascletis Pharma in the upper half of its industry. The industry median Days Sales Outstanding is 68.42. Ascletis Pharma's value of 60.61 is 11.4% below this benchmark. Historically, Ascletis Pharma's own Days Sales Outstanding has ranged from 33.24 to 812.99 over the past decade. While the company's 10-year median is 160.40 vs. the industry median of 68.42, Ascletis Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.42, based on 837 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ascletis Pharma's current Days Sales Outstanding of 60.61 is 11.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Ascletis Pharma and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascletis Pharma's current Days Sales Outstanding is 60.61, which is 62% below median its own 10-year median of 160.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascletis Pharma stock overvalued right now?
Based on GuruFocus' analysis, Ascletis Pharma (ASCLF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $1.21 — trading 5925% above its estimated fair value. The current Days Sales Outstanding is 60.61, which is 62% below median its 10-year median of 160.40 and 11.4% below the Biotechnology industry median of 68.42. Ascletis Pharma's overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Ascletis Pharma (ASCLF), the current Days Sales Outstanding is 60.61 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ascletis Pharma (ASCLF) Overvalued in 2026?
Based on GuruFocus' analysis, Ascletis Pharma stock appears to be overvalued.
The current stock price of $1.21 is trading 5925% above its estimated GF Value™ of $0.02.
GuruFocus considers Ascletis Pharma to be Significantly Overvalued.
Key valuation signals for ASCLF:
Days Sales Outstanding: 60.61 (62% below median its 10-year median of 160.40)
GF Value™: $0.02 vs. price of $1.21 (5925% above fair value)
Industry Position: 11.4% below the Biotechnology median (#268 of 837)
No single metric tells the full story. See the ASCLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ascletis Pharma Inc is an investment holding company. Along with its subsidiaries, it is engaged in the research and development, production, marketing, and sale of pharmaceutical products. The drug candidates of the company in the pipeline in their different stages of development such as ASC30, ASC47, ASC39, ASC36i, ASC35, ASC50, and among others.
38GF Score
Get the complete analysis for ASCLF
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASCLF has been successfully added to your 
